Astellas Discontinues Development of Alzheimer’s Disease Compound FK962

Japan, July 18, 2006 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that it has decided to discontinue development of the Alzheimer’s disease compound FK962.

Astellas started Phase-II trials for FK962 for Alzheimer’s disease in the US and Canada. After careful review of the Phase-II interim analysis clinical data on FK962, Astellas has decided to discontinue further development of FK962 in Alzheimer’s disease since the data reviewed did not indicate clear efficacy of the compound for the treatment of mild to moderate Alzheimer’s disease.

Contacts for inquiries or additional information

Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 Fax: +81-3-5201-7473
http://www.astellas.com